This is a fascinating drug delivery approach focusing on CD-based nanoparticles encapsulating the Toll-like receptor 7 and 8 agonist R848 to target glioblastoma, the most common and aggressive primary brain tumor type. Results show that intravenous monotherapy with CDNP-R848 induces regression of established syngeneic experimental glioma, resulting in increased survival rates compared with unloaded CDNP controls. Mechanistically, CDNP-R848 treatment reshapes the immunosuppressive tumor microenvironment and orchestrates tumor clearing by pro-inflammatory tumor-associated myeloid cells, independently of T cells and NK cells. CDNP-R848 induces tumor regression in experimental glioma by targeting blood-borne macrophages without requiring adaptive immunity
The research was published by Heidelberg University – Verena Turco, Michael Breckwoldt, Michael Platten et al.
See the full article here on nature.com.
